News

Vast’s Lead Drug Candidate Receives Orphan Drug Designation for the Treatment of Respiratory Infection in Patients with Cystic Fibrosis July 16, 2025

Read

Vast Granted Qualified Infectious Disease Product Designation from the FDA March 25, 2025

Read

Vast Awarded $2 Million Grant to Combat Deadly Respiratory Bacteria January 21, 2025

Read

Vast Therapeutics Selected to Present at the American Thoracic Society (ATS)2024 Respiratory Innovation Summit in San Diego, CA April 17, 2024

Read

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer March 7, 2024

Read

Vast Therapeutics Announces Publication of Potential New Treatment for Non-Tuberculosis Mycobacteria Infections January 17, 2024

Read